Matthew W. Emmens

Vertex Pharmaceuticals

Former Chairman, President CEO

Overview

Matthew W. Emmens made an average of $13.6M in compensation at Vertex Pharmaceuticals from 2009 to 2012.

Annual data

2012

In 2012, Matthew W. Emmens earned a total compensation of $6.9M as Former Chairman, President CEO at Vertex Pharmaceuticals.

Ranking781 out of 11,069
Percentile92.9%

Matthew W. Emmens' 2012 compensation ranked 781st out of 11,069 executive pay records tracked by us this year.

Emmens earned more than 92.9% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking34 out of 858
Percentile96.0%

In the industry group of Drugs, Emmens' pay ranked 34th out of 858 executive pay records tracked by us in 2012.

Emmens earned more than 96.0% of executives in this group.

Option Awards$4,612,290
Salary$467,514
Stock Awards$1,786,558
Other$29,667
Total$6,896,029

Emmens received $4.6M in option awards, which accounts for 66.88% of total compensation.

Emmens also received $467.5K in salary, $1.8M in stock awards and $29.7K in other compensation.

2011

In 2011, Matthew W. Emmens earned a total compensation of $13.4M as Former Chairman, President CEO at Vertex Pharmaceuticals.

Ranking191 out of 10,182
Percentile98.1%

Matthew W. Emmens' 2011 compensation ranked 191st out of 10,182 executive pay records tracked by us this year.

Emmens earned more than 98.1% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking10 out of 713
Percentile98.6%

In the industry group of Drugs, Emmens' pay ranked 10th out of 713 executive pay records tracked by us in 2011.

Emmens earned more than 98.6% of executives in this group.

Non-Equity Incentive Plan$3,019,587
Option Awards$7,343,482
Salary$1,163,068
Stock Awards$1,830,927
Other$1,470
Total$13,358,534

Emmens received $7.3M in option awards, which accounts for 54.97% of total compensation.

Emmens also received $3M in non-equity incentive plan, $1.2M in salary, $1.8M in stock awards and $1.5K in other compensation.

2010

In 2010, Matthew W. Emmens earned a total compensation of $14.9M as Former Chairman, President CEO at Vertex Pharmaceuticals.

Ranking139 out of 9,669
Percentile98.6%

Matthew W. Emmens' 2010 compensation ranked 139th out of 9,669 executive pay records tracked by us this year.

Emmens earned more than 98.6% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking7 out of 633
Percentile98.9%

In the industry group of Drugs, Emmens' pay ranked 7th out of 633 executive pay records tracked by us in 2010.

Emmens earned more than 98.9% of executives in this group.

Non-Equity Incentive Plan$2,931,638
Option Awards$8,998,774
Salary$1,129,192
Stock Awards$1,842,727
Other$9,829
Total$14,912,160

Emmens received $9M in option awards, which accounts for 60.35% of total compensation.

Emmens also received $2.9M in non-equity incentive plan, $1.1M in salary, $1.8M in stock awards and $9.8K in other compensation.

2009

In 2009, Matthew W. Emmens earned a total compensation of $19.3M as Chair, President CEO at Vertex Pharmaceuticals.

Ranking49 out of 8,917
Percentile99.5%

Matthew W. Emmens' 2009 compensation ranked 49th out of 8,917 executive pay records tracked by us this year.

Emmens earned more than 99.5% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking8 out of 589
Percentile98.6%

In the industry group of Drugs, Emmens' pay ranked 8th out of 589 executive pay records tracked by us in 2009.

Emmens earned more than 98.6% of executives in this group.

Non-Equity Incentive Plan$2,846,251
Option Awards$10,699,406
Salary$1,002,693
Stock Awards$4,498,687
Other$231,121
Total$19,278,158

Emmens received $10.7M in option awards, which accounts for 55.50% of total compensation.

Emmens also received $2.8M in non-equity incentive plan, $1M in salary, $4.5M in stock awards and $231.1K in other compensation.